Gene · 51441
Papers3,768
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,768
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| YTH N6-methyladenosine RNA binding protein 2 mediated m6A modification of circHIPK2 promotes cellular senescence and osteoarthritis progression by inhibiting autophagy. | Mol Biomed | 2026 | 41894117 | PubTator, text mining | PubMed |
| USP10 deubiquitinase: Physiological function, diseases and therapeutic target (Review). | Int J Mol Med | 2026 | 41891958 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine (m6A) regulates cell cycle progression in diffuse midline glioma (DMG) and confers sensitivity to FTO inhibition. | Cell Death Dis | 2026 | 41888518 | PubTator, text mining | PubMed |
| Decoding the RNA Shield: HNRNPC and YTHDF2 Act as Guardians of Neurons in Parkinson's Disease. | Neurotox Res | 2026 | 41888434 | PubTator, text mining | PubMed |
| Double-edged role of N6-methyladenosine reader YTH structural domain family protein 2 in neurological disorders: Molecular mechanisms and translational prospects. | World J Exp Med | 2026 | 41883454 | PubTator, text mining | PubMed |
| The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification. | PLoS One | 2026 | 41875089 | PubTator, text mining | PubMed |
| Short and Long Non-Coding RNAs in Renal Cell Carcinoma. | Noncoding RNA | 2026 | 41874142 | PubTator, text mining | PubMed |
| m5C RNA methylation is dysregulated by oncogenic herpesviruses via c-Myc signaling to counteract host antiviral factors. | Nucleic Acids Res | 2026 | 41873763 | PubTator, text mining | PubMed |
| Reduced YTHDF2 inhibits PD-L1 expression by stabilizing m6A-containing SPOP mRNA in colorectal cancer. | Cell Death Dis | 2026 | 41872151 | PubTator, text mining | PubMed |
| FTO-CHRM3 axis regulates multiple myeloma progression: a machine learning-based identification. | Ann Hematol | 2026 | 41870649 | PubTator, text mining | PubMed |
| The dual regulatory role of METTL14-mediated m6A modification in tumorigenesis and its underlying mechanisms. | Front Oncol | 2026 | 41858346 | PubTator, text mining | PubMed |
| Epitranscriptomic control of telomere maintenance. | Mol Biol Rep | 2026 | 41854934 | PubTator, text mining | PubMed |
| Dose-Dependent Inhibition of Protein Glycosylation Reveals Crosstalk between Glycosylation and Phosphorylation in EGF Signaling Pathways. | Anal Chem | 2026 | 41843583 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification contributes to anlotinib resistance in osteosarcoma by regulating ferroptosis via the circFAM120B/miR-330-3p/PRKDC axis. | Free Radic Biol Med | 2026 | 41839289 | PubTator, text mining | PubMed |
| Role of solute carrier family 7 member 7 in cancer: opportunities for tumor microenvironment research. | J Immunother Cancer | 2026 | 41825936 | PubTator, text mining | PubMed |
| m6A RNA methylation orchestrates spermatogenesis: decoding the synergistic regulatory network of signaling pathways and ubiquitination modifications. | J Assist Reprod Genet | 2026 | 41824176 | PubTator, text mining | PubMed |
| m6A reader Ythdf proteins control retrotransposon B2 repeat expression and safeguard early embryo development. | EMBO J | 2026 | 41813849 | PubTator, text mining | PubMed |
| Dynamic modulation of N6-methyladenosine by ionizing radiation in human cells. | Biochem Biophys Rep | 2026 | 41810088 | PubTator, text mining | PubMed |
| Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients. | Front Oncol | 2026 | 41809822 | PubTator, text mining | PubMed |
| Roles of RNA-binding proteins in macrophage function regulation and immunotherapy. | Front Cell Dev Biol | 2026 | 41808933 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51441/papers?page=5